Two-dose Pfizer-BioNTech jab provides 70% protection against hospitalization from Omicron varient

The two-dose Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) jab provides 70% protection against severe complications of COVID-19 requiring hospitalization, and 33% protection against COVID-19 infection, during the current Omicron wave.

That is according to Discovery Health, South Africa’s largest private health insurance administrator, which has released real-world analysis of the Omicron outbreak based on 211,000 COVID-19 test results in the African nation.

"A significantly steeper trajectory of new infections relative to prior waves"Test-negative design methodology was used to establish Pfizer and BioNTech's Comirnaty vaccine’s real-world effectiveness against hospital admission from Omicron infection.